Evidence map›Paper›PMID 37084731›Full record

ArticleMolecular cell2023

Proteomic discovery of chemical probes that perturb protein complexes in human cells.

Michael R Lazear, Jarrett R Remsberg, Martin G Jaeger, Katherine Rothamel, Hsuan-Lin Her, Kristen E DeMeester, Evert Njomen, Simon J Hogg, Jahan Rahman, Landon R Whitby and 25 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
13.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 90 citations in OpenAlex.

  1. The cellular landscape of druggable RNA-binding proteins.Nature reviews. Drug discovery · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. [Interferon-α induces disulfidptosis occurrence in human liver cancer cells].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. RNA Splicing as a Therapeutic Target in Cancer.Annual review of pharmacology and toxicology · 2026
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Cysteine reactivity profiling identifies host regulators ofbioRxiv : the preprint server for biology · 2025
    Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors at 9 institutions in 2 countries.

Michael R LazearDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA.
Jarrett R RemsbergDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA. Electronic address: remsberg@scripps.edu.
Martin G JaegerDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA.
Katherine RothamelDepartment of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.
Hsuan-Lin HerDepartment of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.
Kristen E DeMeesterDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA.
Evert NjomenDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA.
Simon J HoggHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
Jahan RahmanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
Landon R WhitbyVividion Therapeutics, 5820 Nancy Ridge Drive, San Diego, CA 92121, USA.
Sang Joon WonDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA.
Michael A SchafrothDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA.
Daisuke OgasawaraDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA.
Minoru YokoyamaDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA.
Garrett L LindseyDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA.
Haoxin LiDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA.
Jason GermainDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA.
Sabrina BarbasDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA.
Joan VaughanClayton Foundation Laboratories for Peptide Biology, The Salk Institute for Biological Studies, La Jolla, CA, USA.
Thomas W HaniganDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA.
Vincent F VartabedianDepartment of Immunology and Microbiology, Scripps Research, La Jolla, CA 92037, USA.
Christopher J ReinhardtDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA.
Melissa M DixDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA.
Seong Joo KooMolecular and Cellular Pharmacology, Discovery Technologies and Molecular Pharmacology, Janssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
Inha HeoMolecular and Cellular Pharmacology, Discovery Technologies and Molecular Pharmacology, Janssen Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
John R TeijaroDepartment of Immunology and Microbiology, Scripps Research, La Jolla, CA 92037, USA.
Gabriel M SimonVividion Therapeutics, 5820 Nancy Ridge Drive, San Diego, CA 92121, USA.
Brahma GhoshDiscovery Chemistry, Janssen Research & Development, Spring House, PA 19477, USA.
Omar Abdel-WahabHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
Kay AhnMolecular and Cellular Pharmacology, Discovery Technologies and Molecular Pharmacology, Janssen Research and Development, Spring House, PA 19477, USA.
Alan SaghatelianClayton Foundation Laboratories for Peptide Biology, The Salk Institute for Biological Studies, La Jolla, CA, USA.
Bruno MelilloDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA; Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA 02142, USA.
Stuart L SchreiberChemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA 02142, USA; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
Gene W YeoDepartment of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.
Benjamin F CravattDepartment of Chemistry, Scripps Research, La Jolla, CA 92037, USA. Electronic address: cravatt@scripps.edu.
Scripps (United States) · USScripps Institution of Oceanography · USMemorial Sloan Kettering Cancer Center · USUniversity of California, San Diego · USJanssen (Belgium) · BEJanssen (United States) · USSalk Institute for Biological Studies · USVividion Therapeutics (United States) · USHarvard University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Functional RNA elements in the human genomeR01HG004659 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Kevin Daniel Corbett, Eugene Wei-Ming Yeo · 2008 to 2026
$12.4M
Chemical Proteomic Platforms for Radically Expanding Cancer DruggabilityR35CA231991 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI BENJAMIN F CRAVATT · 2018 to 2026
$9.5M
Predoctoral and Postdoctoral Training in Cancer Cell BiologyT32CA067754 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEAN Y.J. WANG · 1995 to 2026
$6.5M
A comprehensive binding and functional map of human RNA-binding proteinsU24HG009889 · NHGRI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI GRAVELEY, BRENTON R., YEO, EUGENE WEI-MING · 2022 to 2025
$5.5M
Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment.R01CA238249 · NCI · STANFORD UNIVERSITY · PI CRAVATT, BENJAMIN F, MISCHEL, PAUL S · 2021 to 2025
$3.3M
Stereoisomeric chemical probes for targeting undruggable oncoproteinsF32CA265211 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI REINHARDT, CHRISTOPHER JOHN · 2021 to 2023
$205k
Cancer Research UK CGCATF-2021/100012Howard Hughes Medical Institute GT15176NCI NIH HHS F32 CA265211NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA238249NCI NIH HHS R35 CA231991NCI NIH HHS T32 CA067754NHGRI NIH HHS R01 HG004659NHGRI NIH HHS U24 HG009889
6 · The paper itself

Abstract

Most human proteins lack chemical probes, and several large-scale and generalizable small-molecule binding assays have been introduced to address this problem. How compounds discovered in such "binding-first" assays affect protein function, nonetheless, often remains unclear. Here, we describe a "function-first" proteomic strategy that uses size exclusion chromatography (SEC) to assess the global impact of electrophilic compounds on protein complexes in human cells. Integrating the SEC data with cysteine-directed activity-based protein profiling identifies changes in protein-protein interactions that are caused by site-specific liganding events, including the stereoselective engagement of cysteines in PSME1 and SF3B1 that disrupt the PA28 proteasome regulatory complex and stabilize a dynamic state of the spliceosome, respectively. Our findings thus show how multidimensional proteomic analysis of focused libraries of electrophilic compounds can expedite the discovery of chemical probes with site-specific functional effects on protein complexes in human cells.

Indexed as

ProteomicsTranscription FactorsCysteineHumansLigandsCysteineLigandsTranscription Factorsactivity-based protein profilingchemical probecovalentcysteineproteasomeprotein complexesproteomicssize-exclusion chromatographyspliceosome

Identifiers

PMID37084731
PMCPMC10198961
OpenAlexW4366520850

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.